



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / حسام الدين محمد مغربي

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات : لا يوجد



# **Vascular Dysfunction in Thalassemia Major: Role of Endothelial Monocyte-Activating Polypeptide-II and Oxidative Stress in Relation to Cardiac and Renal Complications**

**Thesis**

*Submitted for the Partial Fulfillment of M.D. Degree in  
Pediatrics*

**Presented By**

***Sarah Mohammed Ibrahim***

*Master Degree in Pediatric, 2013*

*Faculty of Medicine –Ain Shams University*

**Supervised by**

**Prof. Dr. Azza Abdel Gawad Tantawy**

*Professor of Pediatrics*

*Faculty of Medicine - Ain Shams University*

**Dr. Mourad Alfy Ramzy Tadros**

*Consultant of Pediatrics*

*Military Medical Services and Military Medical Academy*

**Prof. Dr. Fatma Soliman Elsayed Ebeid**

*Professor of Pediatrics*

*Faculty of Medicine - Ain Shams University*

**Dr. Fatma Abdel Hamid**

*Assistant Professor of Biochemistry*

*Biotechnology Research Institute - National Research Centre*

**Dr. Nanis Mohammed Salah Eldin**

*Lecturer of Pediatrics*

*Faculty of Medicine - Ain Shams University*

**Faculty of Medicine - Ain Shams University**

**2022**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

لَوْ قُلْتُ رَبِّ  
زِدْنِي عِلْمًا

سورة طه

الآية (١١٤)

صَدَقَ اللَّهُ الْعَظِيمُ

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Azza Abdel Gawad Tantaawy**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Gen. Dr. Mourad Alfy Ramzy Tadros**, Pediatric Consultant in Millatary Academy and Millitary Hospitals, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Prof. Dr. Fatma Soliman Elsayed Ebeid**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Fatma Abdel Hamid**, Assistant Professor of Biochemistry, Biotechnology Research Institute - National Research Centre, for her kindness, supervision and cooperation in this work.*

*I would like to express my thanks to **Dr. Manis Mohammed Salah Eldin**, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University for her support till this work was completed.*

*My deepest appreciation goes to **Prof. Dr. Amira Abdel Moneam Adly**, Professor of Pediatrics, Pediatrics Department, Ain Shams University for her constant guidance and encouragement.*

*I would like to express my deepest thanks to **Prof. Dr. Eman Abdel Rahman Ismail**, Consultant of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her continuous guidance, encouragement, creativity and offering me her precious time for technical experience.*

*I would like to express my deepest gratitude **Dr. Mahitab Morsy Hussein**, Lecturer of Pediatrics, Pediatrics Department, Ain Shams University, for offering me her precious time.*

*Special thanks goes to **Dr. Mervat Abdalhameed Alfeky** Assistant Professor of Clinical Pathology, Clinical Pathology Department, Ain Shams University, for her help and co-operation without which this work could not be possible*

*Also, special thanks to my colleague **Marwa Adel Hashem Nasr** for her help*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

*Sarah Mohammed Ibrahim*

# List of Contents

Title	Page No.
List of Tables .....	i
List of Figures .....	iv
List of Abbreviations.....	viii
Abstract .....	xii
Introduction .....	1
Aim of the Work.....	5
Review of Literature	
<b>Chpater (1): Thalassemia</b> .....	6
Role of Oxidant Injury in $\beta$ -Thalassemia Ineffective Erythropoiesis .....	8
Role of Inflammatory Cytokines in Ineffective Erythropoiesis in $\beta$ -Thalassemia Patients.....	9
Clinical picture and complications of $\beta$ thalassemia.....	9
Laboratory diagnosis .....	11
Management of $\beta$ -thalassemia .....	14
<b>Chpater (2): Oxidative Stress in Thalassemia</b> .....	27
Intracellular oxidative events.....	28
Protective mechanisms in RBCS .....	34
Extracellular oxidative events.....	36
Antioxidant enzymes .....	37
<b>Chpater (3): Endothelial Monocyte Activating Polypeptide II</b> ...	41
Discovery and isolation .....	41
ProEMAP/p43 and EMAP II (gene and protein) .....	41
Biological functions of proEMAP/p43 and EMAP II.....	45
Mechanistic studies on proEMAP/p43 and EMAPII effects.....	51
From proEMAP/p43 to EMAP II.....	52
EMAP II in different diseases .....	54
EMAP II and therapy .....	56

# List of Contents *(Cont...)*

Title	Page No.
<b>Chpater (4): Endothelin-1 gene Polymorphism.....</b>	<b>58</b>
The Endothelin System.....	58
Clinical impact of ET-1 .....	62
ET-1 and ROS .....	63
The pro-inflammatory effect of ET-1.....	65
ET-1 polymorphism.....	66
Patients and Methods.....	68
Results .....	86
Discussion .....	135
Summary .....	161
Conclusion .....	167
Recommendations .....	168
References .....	169
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	Comparison of the three main iron chelators.....	17
<b>Table 2:</b>	Ongoing Clinical Assessment of New Treatments for $\beta$ -Thalassemia.....	23
<b>Table 3:</b>	Summary of all reported biological functions and features of EMAP II .....	46
<b>Table 4:</b>	Expression of endothelin receptors and cells producing ET-1 .....	60
<b>Table 5:</b>	Factors, which stimulate and inhibit release of ET-1 .....	61
<b>Table 6:</b>	Clinical data of patients with $\beta$ -thalassemia major.....	87
<b>Table 7:</b>	Laboratory data of the studied $\beta$ -TM patients .....	88
<b>Table 8:</b>	Comparison between $\beta$ -TM patients and controls as regards EMAP II and oxidative stress markers .....	89
<b>Table 9:</b>	Genotype and allele frequencies of Endothelin-1 gene polymorphism (G8002A) in patients with $\beta$ -TM and healthy controls .....	94
<b>Table 10:</b>	Clinical characteristics of patients with $\beta$ -thalassemia major in relation to Endothelin-1 gene polymorphism (G8002A).....	96
<b>Table 11:</b>	Laboratory characteristics of patients with $\beta$ -thalassemia major in relation to Endothelin-1 gene polymorphism (G8002A).....	98
<b>Table 12:</b>	Clinical data of $\beta$ -TM patients with mean serum ferritin above or lower than 2500 $\mu\text{g/L}$ .....	100
<b>Table 13:</b>	Laboratory data among $\beta$ -TM patients with mean serum ferritin above or lower than 2500 $\mu\text{g/L}$ .....	101



# List of Tables *(Cont...)*

Table No.	Title	Page No.
<b>Table 14:</b>	EMAP II and MDA levels in relation to clinical characteristics and iron overload of $\beta$ -TM patients.....	102
<b>Table 15:</b>	Receiver operating characteristic curve (ROC) for EMAP II as a predictor of heart disease in $\beta$ -TM patients .....	107
<b>Table 16:</b>	Receiver operating characteristic curve (ROC) for EMAP II as a predictor of pulmonary hypertension risk in $\beta$ -TM patients .....	108
<b>Table 17:</b>	Receiver operating characteristic curve (ROC) for EMAP II as a predictor of nephropathy in $\beta$ -TM patients .....	109
<b>Table 18:</b>	Antioxidant levels (superoxide dismutase, glutathione peroxidase and reduced glutathione) in relation to clinical characteristics and iron overload of $\beta$ -TM patients .....	110
<b>Table 19:</b>	Antioxidant levels (glutathione reductase and catalase) in relation to clinical characteristics and iron overload of $\beta$ -TM patients .....	112
<b>Table 20:</b>	Correlation between EMAP II and MDA levels and clinical and laboratory data of $\beta$ -TM patients.....	114
<b>Table 21:</b>	Multivariate linear regression analysis for factors affecting EMAP II levels in $\beta$ -TM patients .....	122
<b>Table 22:</b>	Multivariate linear regression analysis for factors affecting MDA levels in $\beta$ -TM patients .....	123

# List of Tables *(Cont...)*

Table No.	Title	Page No.
<b>Table 23:</b>	Correlation between antioxidant levels (superoxide dismutase, glutathione peroxidase and reduced glutathione) and clinical and laboratory data of $\beta$ -TM patients .....	124
<b>Table 24:</b>	Multivariate linear regression analysis for factors affecting superoxide dismutase levels in $\beta$ -TM patients.....	127
<b>Table 25:</b>	Multivariate linear regression analysis for factors affecting glutathione peroxidase levels in $\beta$ -TM patients .....	128
<b>Table 26:</b>	Multivariate linear regression analysis for factors affecting reduced glutathione levels in $\beta$ -TM patients.....	129
<b>Table 27:</b>	Correlation between antioxidant levels (glutathione reductase and catalase) and clinical and laboratory data of $\beta$ -TM patients .....	130
<b>Table 28:</b>	Multivariate linear regression analysis for factors affecting glutathione reductase levels in $\beta$ -TM patients .....	133
<b>Table 29:</b>	Multivariate linear regression analysis for factors affecting catalase levels in $\beta$ -TM patients .....	134

# List of Figures

Fig. No.	Title	Page No.
<b>Figure 1:</b>	Mechanism of IE and hemolysis in thalassemia.....	7
<b>Figure 2:</b>	$\beta$ -thalassemia risk factors, complications and iron chelator-related adverse events.....	10
<b>Figure 3:</b>	Current and future therapies for beta-thalassemia major .....	14
<b>Figure 4:</b>	Amelioration of free iron species by iron chelators and antioxidants.....	18
<b>Figure 5:</b>	Intracellular oxidative events and Protective mechanisms in RBCs and the circulation.....	28
<b>Figure 6:</b>	Oxidative events in the bone marrow and circulation.....	33
<b>Figure 7:</b>	Structure of the human EMAP II gene .....	42
<b>Figure 8:</b>	Functional domains within the proEMAP/p43-EMAP II protein.....	44
<b>Figure 9:</b>	Anti-angiogenic activities of EMAP II on endothelial cells .....	49
<b>Figure 10:</b>	ETA receptor-mediated VSMC signalling pathways .....	62
<b>Figure 11:</b>	G(8002)A endothelin-1 genotypes.....	84
<b>Figure 12:</b>	EMAP II levels among $\beta$ -TM patients and healthy controls. ....	90
<b>Figure 13:</b>	MDA levels among $\beta$ -TM patients and healthy controls. ....	90
<b>Figure 14:</b>	Superoxide dismutase levels among $\beta$ -TM patients and healthy controls.....	91
<b>Figure 15:</b>	Glutathione peroxidase levels among $\beta$ -TM patients and healthy controls.....	91

# List of Figures *(Cont...)*

Fig. No.	Title	Page No.
<b>Figure 16:</b>	Reduced glutathione levels among $\beta$ -TM patients and healthy controls.....	92
<b>Figure 17:</b>	Glutathione reductase levels among $\beta$ -TM patients and healthy controls.....	92
<b>Figure 18:</b>	Catalase levels among $\beta$ -TM patients and healthy controls. ....	93
<b>Figure 19:</b>	G(8002)A endothelin-1 genotypes among $\beta$ -TM patients.....	95
<b>Figure 20:</b>	Association of Endothelin-1 gene polymorphism (G8002A) and heart disease, pulmonary hypertension risk and nephropathy among $\beta$ -TM patients.....	97
<b>Figure 21:</b>	EMAP II levels in relation to heart disease among $\beta$ -TM patients.....	103
<b>Figure 22:</b>	EMAP II levels in relation to pulmonary hypertension risk among $\beta$ -TM patients.....	104
<b>Figure 23:</b>	EMAP II levels in relation to nephropathy among $\beta$ -TM patients.....	104
<b>Figure 24:</b>	EMAP II levels in relation to compliance to therapy among $\beta$ -TM patients. ....	105
<b>Figure 25:</b>	EMAP II levels in relation to ferritin cutoff 2500 $\mu$ g/L among $\beta$ -TM patients. ....	105
<b>Figure 26:</b>	EMAP II levels in relation to endothelin-1 genotypes among $\beta$ -TM patients. ....	106
<b>Figure 27:</b>	EMAP II levels in relation to endothelin-1 GG and GA genotypes versus AA genotype among $\beta$ -TM patients.....	106
<b>Figure 28:</b>	Receiver operating characteristic curve (ROC) for EMAP II as a predictor of heart disease in $\beta$ -TM patients.....	107

# List of Figures *(Cont...)*

Fig. No.	Title	Page No.
<b>Figure 29:</b>	Receiver operating characteristic curve (ROC) for EMAP II as a predictor of pulmonary hypertension risk in $\beta$ -TM patients .....	108
<b>Figure 30:</b>	Receiver operating characteristic curve (ROC) for EMAP II as a predictor of nephropathy in $\beta$ -TM patients.....	109
<b>Figure 31:</b>	Correlation between EMAP II level and systolic blood pressure among $\beta$ -TM patients. ....	115
<b>Figure 32:</b>	Correlation between EMAP II level and transfusion index among $\beta$ -TM patients. ....	116
<b>Figure 33:</b>	Correlation between EMAP II level and LDH level among $\beta$ -TM patients.....	116
<b>Figure 34:</b>	Correlation between EMAP II level and serum ferritin among $\beta$ -TM patients. ....	117
<b>Figure 35:</b>	Correlation between EMAP II level and superoxide dismutase among $\beta$ -TM patients. ....	117
<b>Figure 36:</b>	Correlation between EMAP II level and glutathione reductase among $\beta$ -TM patients. ....	118
<b>Figure 37:</b>	Correlation between EMAP II level and catalase among $\beta$ -TM patients. ....	118
<b>Figure 38:</b>	Correlation between MDA and systolic blood pressure among $\beta$ -TM patients.....	119
<b>Figure 39:</b>	Correlation between MDA and WBC count among $\beta$ -TM patients.....	119
<b>Figure 40:</b>	Correlation between MDA and LDH among $\beta$ -TM patients. ....	120

# List of Figures (Cont...)

Fig. No.	Title	Page No.
<b>Figure 41:</b>	Correlation between MDA and serum ferritin among $\beta$ -TM patients. ....	120
<b>Figure 42:</b>	Correlation between MDA and superoxide dismutase among $\beta$ -TM patients. ....	121
<b>Figure 43:</b>	Correlation between MDA and catalase among $\beta$ -TM patients.....	121
<b>Figure 44:</b>	Correlation between glutathione peroxidase and glutathione reductase among $\beta$ -TM patients.....	125
<b>Figure 45:</b>	Correlation between superoxide dismutase and ferritin among $\beta$ -TM patients. ....	126
<b>Figure 46:</b>	Correlation between glutathione peroxidase and indirect bilirubin among $\beta$ -TM patients. ....	126
<b>Figure 47:</b>	Correlation between glutathione reductase and LDH among $\beta$ -TM patients. ....	131
<b>Figure 48:</b>	Correlation between glutathione reductase and ferritin among $\beta$ -TM patients. ....	132
<b>Figure 49:</b>	Correlation between glutathione reductase and catalase among $\beta$ -TM patients. ....	132

# List of Abbreviations

Abb.	Full term
ACS .....	<i>Acute chest syndrome</i>
ALT.....	<i>Alanine aminotransferase</i>
ARS .....	<i>Aminoacyl tRNA synthetase</i>
AST.....	<i>Aspartate aminotransferase</i>
AST.....	<i>Aspartate aminotransferase</i>
BMI .....	<i>Body mass index</i>
BP .....	<i>Blood pressure</i>
CAT .....	<i>Catalase</i>
CBC .....	<i>Complete blood count</i>
CDS .....	<i>Coding sequence</i>
cm .....	<i>Centimeters</i>
CRS .....	<i>Cardiorenal syndrome</i>
DAG .....	<i>Diacylglycerol</i>
DFO .....	<i>Deferoxamine</i>
DFP .....	<i>Deferiprone</i>
DFX .....	<i>Deferasirox</i>
DOC1.....	<i>Downregulated in ovarian cancer 1</i>
EC.....	<i>Endothelial cells</i>
ELISA .....	<i>Enzyme-linked immunosorbent assay</i>
EMAP-II .....	<i>Endothelial monocyte-activating polypeptide-II</i>
eNOS .....	<i>Endothelial nitric oxide synthase</i>
ET-1 .....	<i>Endothelin-1</i>
Fe .....	<i>Iron</i>
FN.....	<i>Fibronectin</i>
G-6-PD .....	<i>Glucose-6-phosphate dehydrogenase</i>
G8002A .....	<i>Endothelin-1 gene polymorphism</i>
GDF11 .....	<i>Growth differentiation factor 11</i>
GFR .....	<i>Glomerular filtration</i>